The Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2010
Citation and commencement1.
This Order may be cited as the Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2010 and shall come into operation on 16th April 2010.
Interpretation2.
(1)
(2)
Amendments to the 2001 Order3.
In Part 1 of the Schedule to the 2001 Order—
(a)
in paragraph 1(a), after “Methcathinone”, insert —
(b)
“4–Methylmecathinone”.
(c)
“(q)
Any compound (not being bupropion, diethylpropion, pyrovalerone or a compound for the time being specified in sub-paragraph (a) above) structurally derived from 2–amino-1-phenyl-1–propanone by modification in any of the following ways, that is to say,
(i)
by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
(ii)
by substitution at the 3-position with an alkyl substituent;
(iii)
by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.”.
Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 12th April 2010
Section 7(3) of the Misuse of Drugs Act 1971 (“the 1971 Act”) requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under the 1971 Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) Order (Northern Ireland) 2001 by inserting into Part 1 of the Schedule to that Order 4-Methylmethcathinone (commonly referred to as Mephedrone) and other cathinone derivatives.